leadf
logo-loader
viewInnoCan Pharma

Full interview: InnoCan Pharma signs deal with ADVA Biotechnology to produce Exosomes with CBD

InnoCann Pharma (CSE: INNO) CEO Iris Bincovich joined Steve Darling from Proactive Vancouver with news the company has signed a Letter of Intent with ADVA Bio-Technology for exosome manufacturing and development.

Bincovich telling Proactive InnoCan intends to load the produced exosomes with CBD and then will be used in the development of therapy for COVID-19 disease and other indications of the central nervous system.

Quick facts: InnoCan Pharma

Price: 0.45 CAD

CSE:INNO
Market: CSE
Market Cap: $79.07 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Loop Insights getting ready to rumble as platform wallet being used by the...

Loop Insights (CVE: MTRX- OTCQB: RACMF) CEO Rob Anson joined Steve Darling from Proactive with big news that Loop's Wallet pass platform will engage global boxing fans during the WBC super-middleweight championship fight, featuring champion Saul "Canelo" Alvarez and challenger Avni...

11 hours, 54 minutes ago

2 min read